MetaTOC stay on top of your field, easily

Pozen Inc. v. Par Pharmaceutical, Inc.: "Fuzzy" limitations and the doctrine of equivalents

,

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector

Published online on

Abstract

In Pozen Inc. v. Par Pharmaceutical, Inc., 696 F.3d 1151 (Fed. Cir. 2012), the Federal Circuit addressed the application of the doctrine of equivalents to ‘fuzzy’ claim limitations – i.e., claim limitations without set boundaries. The Federal Circuit found that even when the District Court has construed such limitations to have a definite meaning, the application of the doctrine of equivalents is not precluded. This case report presents the arguments made to the Federal Circuit by the parties and how the Federal Circuit addressed these issues.